Intraperitoneal Bevacizumab (Bev) for Control of Malignant Ascites Due to Advanced-Stage Gastrointestinal Cancers (Gi): a Multicenter Double-Blind, Placebo (Pl)-Controlled, Randomized Phase Ii Study. Aio Sup-0108

Karin Jordan(Martin Luther University Halle-Wittenberg), S. Hegewisch-Becker(HOPE Clinic), Djordje Atanackovic(University of Maryland, Baltimore), Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), C. Gog(Goethe University Frankfurt), Tim Luetkens(University of Maryland, Baltimore), E. Späth‐Schwalbe(Vivantes Klinikum), Werner Freier(Mayo Clinic in Florida), B. Killing, Axel Hinke, Jörn Rüssel(Martin Luther University Halle-Wittenberg), Dirk Medgenberg(Klinikum Leverkusen), Uwe Pelzer(Humboldt-Universität zu Berlin), Siegfried Wagner(Deggendorf Institute of Technology), Dirk Arnold(Asklepios Klinik Altona)
Annals of Oncology
September 1, 2014
10.1093/annonc/mdu356.8
Cited by 0

Related Papers

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2016|1.1k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k